Top Page
RemeGen Co. Ltd. Class H
(9995)
RemeGen Co. Ltd. Class H (9995) vs. S&P 500 (SPY)
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
RemeGen Co. Ltd. Class H Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 1.08B | 767.77M | 1.42B | 0.00 | 0.00 | Gross Profit |
| 822.99M | 497.84M | 1.36B | 0.00 | 0.00 | EBIT |
| -1.50B | -993.07M | 281.92M | -668.55M | -386.63M | EBITDA |
| -1.25B | -805.70M | 402.05M | -661.56M | -343.85M | Net Income Common Stockholders |
| -1.51B | -997.84M | 276.26M | -727.09M | -473.94M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 743.39M | 2.07B | 1.76B | 2.77B | 34.55M | Total Assets |
| 5.53B | 6.02B | 4.16B | 4.12B | 689.31M | Total Debt |
| 1.26B | 165.03M | 102.78M | 197.69M | 65.36M | Net Debt |
| 550.91M | -1.90B | -1.65B | -2.57B | 30.82M | Total Liabilities |
| 2.09B | 1.04B | 712.79M | 523.07M | 921.28M | Stockholders Equity |
| 3.44B | 4.98B | 3.45B | 3.59B | -231.97M |
| Cash Flow | Free Cash Flow | |||
| -2.35B | -2.02B | -353.71M | -1.14B | -347.95M | Operating Cash Flow |
| -1.50B | -1.26B | 263.63M | -660.08M | -282.75M | Investing Cash Flow |
| -817.65M | -841.56M | -637.95M | -479.06M | -95.10M | Financing Cash Flow |
| 978.31M | 2.43B | -626.90M | 3.90B | 407.32M |
RemeGen Co. Ltd. Class H Technical Analysis
RemeGen Co. Ltd. Class H Peers Comparison
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Co., Ltd. has released its unaudited financial data for the first quarter of 2025, prepared according to Chinese accounting principles. The report has been reviewed by the company’s audit committee but not by independent auditors, and stakeholders are advised to exercise caution when dealing with the company’s securities.
RemeGen Co., Ltd. has announced a board meeting scheduled for April 28, 2025, to consider and approve the unaudited first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance and could impact its market positioning and stakeholder confidence.
RemeGen Co., Ltd. held its 2025 second extraordinary general meeting (EGM) on April 2, 2025, where shareholders approved the appointment of Mr. Wen Qingkai as an executive director and member of the Strategy Committee. This appointment is expected to enhance the company’s strategic direction and governance, potentially impacting its operational effectiveness and stakeholder confidence.
RemeGen Co., Ltd. announced the composition of its board of directors and their respective roles within the company. This announcement is significant as it outlines the leadership structure, which plays a crucial role in guiding the company’s strategic direction and governance. The board includes executive, non-executive, and independent non-executive directors, with various members chairing or participating in key committees such as the Audit, Remuneration and Appraisal, Nomination, and Strategy Committees. This structured leadership is expected to enhance the company’s operational efficiency and strategic decision-making, potentially impacting its market positioning and stakeholder confidence.
RemeGen Co., Ltd. reported a significant increase in revenue for 2024, driven by strong sales of its key products, telitacicept and disitamab vedotin. The company has made notable advancements in its product pipeline, including FDA fast track designation for telitacicept for primary Sjögren’s Syndrome and achieving primary endpoints in clinical trials for generalized myasthenia gravis. Disitamab vedotin also showed promising results in various cancer treatments, enhancing RemeGen’s position in the biopharmaceutical industry.
RemeGen Co., Ltd. announced that its Phase III study results for telitacicept, a dual-target fusion protein drug for treating generalized myasthenia gravis, have been selected for a major presentation at the 2025 American Academy of Neurology Annual Meeting. This recognition highlights the potential impact of telitacicept on the treatment landscape of neurological disorders, although there is no assurance of its successful market launch.
RemeGen Co., Ltd. has announced that its board of directors will convene on March 27, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the potential payment of dividends, which could impact shareholder returns and reflect the company’s financial health.
RemeGen Co., Ltd. has announced its 2025 second extraordinary general meeting (EGM) scheduled for April 2, 2025, where the primary agenda is to consider and approve the appointment of Mr. Wen Qingkai as an executive director. This appointment could potentially influence the company’s strategic direction and governance, impacting stakeholders and possibly enhancing its industry positioning.
RemeGen Co., Ltd. announced the nomination of Mr. Wen Qingkai as a candidate for the position of executive director and member of the strategy committee, pending approval at the upcoming extraordinary general meeting. Mr. Wen, who has extensive experience in capital operations and corporate governance, currently oversees financing activities and internal controls at RemeGen. His appointment is expected to strengthen the company’s strategic direction and operational oversight.
RemeGen Co., Ltd. has released its preliminary financial results for 2024, showing a significant increase in total operating revenue by 58.40% compared to the previous year. However, the company continues to report a net loss, albeit slightly reduced from the previous year. The company’s total assets and owner’s equity have decreased slightly, indicating ongoing financial challenges. Investors are advised to consider these preliminary results with caution as they are unaudited and subject to change in the final annual report.